Delayed
Warsaw S.E.
08:12:46 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
49
PLN
|
+0.31%
|
|
-3.54%
|
-14.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
718.7
|
903.1
|
1,120
|
1,139
|
1,329
|
1,129
|
-
|
-
|
Enterprise Value (EV)
1 |
718.7
|
744.3
|
1,042
|
1,139
|
1,329
|
1,056
|
1,148
|
1,129
|
P/E ratio
|
-
|
-26
x
|
-14.4
x
|
-10.7
x
|
-14.3
x
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.4
x
|
24.4
x
|
30.2
x
|
16.6
x
|
19.8
x
|
7.44
x
|
5.19
x
|
-
|
EV / Revenue
|
19.4
x
|
20.1
x
|
28.1
x
|
16.6
x
|
19.8
x
|
6.95
x
|
5.28
x
|
-
|
EV / EBITDA
|
-
|
-31.9
x
|
-15.9
x
|
-17.4
x
|
-14.8
x
|
-12.8
x
|
-34.8
x
|
-
|
EV / FCF
|
-
|
-11.2
x
|
-14.9
x
|
-
|
-
|
-8
x
|
-11.4
x
|
-941
x
|
FCF Yield
|
-
|
-8.95%
|
-6.71%
|
-
|
-
|
-12.5%
|
-8.75%
|
-0.11%
|
Price to Book
|
-
|
4.04
x
|
6.61
x
|
-
|
-
|
8.74
x
|
31.7
x
|
-
|
Nbr of stocks (in thousands)
|
15,971
|
18,355
|
18,355
|
23,120
|
23,120
|
23,120
|
-
|
-
|
Reference price
2 |
45.00
|
49.20
|
61.00
|
49.25
|
57.50
|
48.85
|
48.85
|
48.85
|
Announcement Date
|
4/9/20
|
3/16/21
|
3/15/22
|
3/24/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
37
|
36.95
|
37.08
|
68.44
|
67.3
|
151.8
|
217.5
|
-
|
EBITDA
1 |
-
|
-23.31
|
-65.31
|
-65.52
|
-89.98
|
-82.6
|
-33
|
-
|
EBIT
1 |
-
|
-35.67
|
-77.87
|
-78.42
|
-100.9
|
-160
|
-93.6
|
-
|
Operating Margin
|
-
|
-96.53%
|
-210%
|
-114.59%
|
-150.01%
|
-105.38%
|
-43.03%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-30.62
|
-77.42
|
-79.2
|
-92.11
|
-161.2
|
-118.6
|
-
|
Net income
1 |
-
|
-31.69
|
-77.53
|
-83.78
|
-92.11
|
-161.2
|
-118.6
|
-
|
Net margin
|
-
|
-85.76%
|
-209.1%
|
-122.42%
|
-136.88%
|
-106.17%
|
-54.54%
|
-
|
EPS
|
-
|
-1.890
|
-4.224
|
-4.600
|
-4.020
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-66.58
|
-69.85
|
-
|
-
|
-132
|
-100.4
|
-1.2
|
FCF margin
|
-
|
-180.18%
|
-188.38%
|
-
|
-
|
-86.9%
|
-46.18%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/9/20
|
3/16/21
|
3/15/22
|
3/24/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
-
|
34.62
|
18.32
|
15.25
|
16.24
|
17.71
|
24.5
|
EBITDA
1 |
-
|
2.242
|
-11.55
|
-24.61
|
-
|
-24.29
|
-17.3
|
EBIT
1 |
-
|
-0.6844
|
-18.1
|
-31.64
|
-
|
-26.92
|
-20.25
|
Operating Margin
|
-
|
-1.98%
|
-98.84%
|
-207.43%
|
-
|
-152%
|
-82.65%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-11.8
|
-8.525
|
-17.6
|
-28.51
|
-18.25
|
-27.75
|
-17.8
|
Net margin
|
-
|
-24.63%
|
-96.07%
|
-186.88%
|
-112.42%
|
-156.74%
|
-72.65%
|
EPS
|
-0.6430
|
-
|
-
|
-
|
-0.7900
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/23/22
|
3/24/23
|
5/16/23
|
9/13/23
|
11/29/23
|
3/13/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
18.4
|
-
|
Net Cash position
1 |
-
|
159
|
78.2
|
-
|
-
|
73.6
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.558
x
|
-
|
Free Cash Flow
1 |
-
|
-66.6
|
-69.8
|
-
|
-
|
-132
|
-100
|
-1.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-39.4%
|
-
|
-
|
-39.9%
|
-29.5%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
12.20
|
9.230
|
-
|
-
|
5.590
|
1.540
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
34.2
|
-
|
-
|
-
|
6.45
|
9.2
|
14.4
|
Capex / Sales
|
-
|
92.5%
|
-
|
-
|
-
|
4.25%
|
4.23%
|
-
|
Announcement Date
|
4/9/20
|
3/16/21
|
3/15/22
|
3/24/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
48.85
PLN Average target price
73.12
PLN Spread / Average Target +49.69% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.78% | 280M | | -2.63% | 102B | | +1.62% | 96.29B | | +2.01% | 22.18B | | -16.67% | 21.2B | | -9.77% | 18.31B | | -38.74% | 17.38B | | -13.21% | 16.36B | | +5.41% | 13.97B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|